Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study

Clinical and Experimental Rheumatology

Gabriele Pozzato¹  Armando Gabrielli¹  Marco Lenzi¹  Maurizio Pietrogrande¹  Carlo Donada¹  Clodoveo Ferri¹  Francesco Saccardo¹  Anna Linda Zignego¹  Giuseppe Monti¹  Salvatore De Vita¹  Cesare Mazzaro¹  Massimo Galli¹ 

关键词: Hepatitis C virus;    mixed cryoglobulinemia;    antiviral therapy;    HCV genotype;    cryoglobulinemic glomerulonephritis;    Mixed cryoglobulinemia;    hepatitis C virus;    antiviral therapy;    HCV genotype;    cryoglobulinemic glomerulonephritis;   

DOI  :  

学科分类：医学（综合）

来源: Pacini Editore SpA

【 摘 要 】

OBJECTIVES: The aim of the present study is to provide information on clinical outcome of the patients affected by HCV-positive mixed cryoglobulinemia (MC) treated with PEG-IFN and Ribavirin for 6 or 12 months according to the HCV genotype. METHODS: Eighty-six patients (42 women and 44 men) were enrolled in 8 Italian centres. All the patients had MC in the active phase of the disease. The patients received Peginterferon alfa-2b 1.5 mcg/kg/once a week (QW) and daily oral Ribavirin (800/1,000/1,200) according to their body weight for 48 weeks for genotype 1 and 4 and for 24 weeks for genotypes 2 and 3. RESULTS: In the 44 patients who underwent 12 months of therapy, 17 cases (39%) could be considered as `non-responders` and 11 relapsed, therefore only 16 patients (36%) obtained a sustained virological response. In the 42 patients who underwent six months of therapy only 7 cases (17%) could be considered as `non-responders` and 8 relapsed, therefore 27 patients (64%) obtained a sustained virological response. Purpura score dropped in both group (p

【 授权许可】

Unknown